Ariella B. Hanker, Ph.D.
Affiliations: | 2009 | Genetics & Molecular Biology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Molecular Biology, Cell BiologyGoogle:
"Ariella Hanker"Parents
Sign in to add mentor| Channing J. Der | grad student | 2009 | UNC Chapel Hill | |
| (Ras family GTPases involved in breast cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin CC, Chang TC, Wang Y, et al. (2024) PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature Communications. 15: 2287 |
| Marquez-Palencia M, Reza Herrera L, Parida PK, et al. (2024) AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer. Cancer Research |
| Xu Y, Wang Z, Sjöström M, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology |
| Lin CC, Chang TC, Wang Y, et al. (2023) Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square |
| Kim BJ, Zheng ZY, Lei JT, et al. (2023) Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Research Communications. 3: 1366-1377 |
| Marin A, Mamun AA, Patel H, et al. (2023) Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Research |
| Liu S, Xie SM, Liu W, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research : Bcr. 25: 62 |
| Liu S, Xie SM, Liu W, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Research Square |
| Lee KM, Lin CC, Servetto A, et al. (2022) Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer. Cancer Immunology Research |
| Parida PK, Marquez-Palencia M, Nair V, et al. (2022) Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metabolism. 34: 90-105.e7 |